NasdaqGS:GILDBiotechs
Gilead (GILD) Wins FDA Approval For Trodelvy In First Line Triple Negative Breast Cancer
Gilead Sciences (NasdaqGS:GILD) received FDA approval for Trodelvy as a first-line treatment for adult patients with advanced or metastatic triple-negative breast cancer.
The approval covers use as monotherapy and in combination with Keytruda for PD-L1 positive disease.
Trodelvy is a first-in-class Trop-2 directed antibody-drug conjugate with overall survival data across multiple indications.
Gilead Sciences is best known for its antiviral therapies, and Trodelvy illustrates how the company...